462 related articles for article (PubMed ID: 32817589)
1. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.
Chen X; Zhang J; Ruan W; Huang M; Wang C; Wang H; Jiang Z; Wang S; Liu Z; Liu C; Tan W; Yang J; Chen J; Chen Z; Li X; Zhang X; Xu P; Chen L; Xie R; Zhou Q; Xu S; Irwin DL; Fan JB; Huang J; Lin T
J Clin Invest; 2020 Dec; 130(12):6278-6289. PubMed ID: 32817589
[TBL] [Abstract][Full Text] [Related]
2. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.
Ruan W; Chen X; Huang M; Wang H; Chen J; Liang Z; Zhang J; Yu Y; Chen S; Xu S; Hu T; Li X; Guo Y; Jiang Z; Chen Z; Huang J; Lin T; Fan JB
Clin Epigenetics; 2021 Apr; 13(1):91. PubMed ID: 33902700
[TBL] [Abstract][Full Text] [Related]
3. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples.
Renard I; Joniau S; van Cleynenbreugel B; Collette C; Naômé C; Vlassenbroeck I; Nicolas H; de Leval J; Straub J; Van Criekinge W; Hamida W; Hellel M; Thomas A; de Leval L; Bierau K; Waltregny D
Eur Urol; 2010 Jul; 58(1):96-104. PubMed ID: 19674832
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of methylated PENK gene for early detection of bladder cancer using urine DNA.
Oh TJ; Lim E; Bang BR; Lee JJ; Na YG; Shin JH; Lim JS; Song KH; An S
BMC Cancer; 2022 Nov; 22(1):1195. PubMed ID: 36403035
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
7. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
[TBL] [Abstract][Full Text] [Related]
8. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
[TBL] [Abstract][Full Text] [Related]
9. UroMark-a urinary biomarker assay for the detection of bladder cancer.
Feber A; Dhami P; Dong L; de Winter P; Tan WS; Martínez-Fernández M; Paul DS; Hynes-Allen A; Rezaee S; Gurung P; Rodney S; Mehmood A; Villacampa F; de la Rosa F; Jameson C; Cheng KK; Zeegers MP; Bryan RT; James ND; Paramio JM; Freeman A; Beck S; Kelly JD
Clin Epigenetics; 2017; 9():8. PubMed ID: 28163793
[TBL] [Abstract][Full Text] [Related]
10. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments.
Chung W; Bondaruk J; Jelinek J; Lotan Y; Liang S; Czerniak B; Issa JP
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1483-91. PubMed ID: 21586619
[TBL] [Abstract][Full Text] [Related]
11. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine.
Chen PC; Tsai MH; Yip SK; Jou YC; Ng CF; Chen Y; Wang X; Huang W; Tung CL; Chen GC; Huang MM; Tong JH; Song EJ; Chang DC; Hsu CD; To KF; Shen CH; Chan MW
BMC Med Genomics; 2011 May; 4():45. PubMed ID: 21599969
[TBL] [Abstract][Full Text] [Related]
12. High Detection Rate for Non-Muscle-Invasive Bladder Cancer Using an Approved DNA Methylation Signature Test.
Steinbach D; Kaufmann M; Hippe J; Gajda M; Grimm MO
Clin Genitourin Cancer; 2020 Jun; 18(3):210-221. PubMed ID: 32139301
[TBL] [Abstract][Full Text] [Related]
13. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
14. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
[TBL] [Abstract][Full Text] [Related]
15. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.
Hermanns T; Savio AJ; Olkhov-Mitsel E; Mari A; Wettstein MS; Saba K; Bhindi B; Kuk C; Poyet C; Wild PJ; Noon A; Bashir S; Juvet T; Rendon RA; Waltregny D; van der Kwast T; Finelli A; Kulkarni GS; Fleshner NE; Lo K; Bapat B; Zlotta AR
Urol Oncol; 2020 Jun; 38(6):603.e1-603.e7. PubMed ID: 32081560
[TBL] [Abstract][Full Text] [Related]
16. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel.
Dulaimi E; Uzzo RG; Greenberg RE; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Mar; 10(6):1887-93. PubMed ID: 15041703
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation.
Reinert T; Borre M; Christiansen A; Hermann GG; Ørntoft TF; Dyrskjøt L
PLoS One; 2012; 7(10):e46297. PubMed ID: 23056278
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
[TBL] [Abstract][Full Text] [Related]
19. Size-based enrichment of exfoliated tumor cells in urine increases the sensitivity for DNA-based detection of bladder cancer.
Andersson E; Steven K; Guldberg P
PLoS One; 2014; 9(4):e94023. PubMed ID: 24732047
[TBL] [Abstract][Full Text] [Related]
20. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors.
Fitzgerald JM; Ramchurren N; Rieger K; Levesque P; Silverman M; Libertino JA; Summerhayes IC
J Natl Cancer Inst; 1995 Jan; 87(2):129-33. PubMed ID: 7707384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]